| Literature DB >> 27403562 |
Carla Daniela Robles-Espinoza1,2, Nicola D Roberts1,3, Shuyang Chen4, Finbarr P Leacy5,6, Ludmil B Alexandrov3, Natapol Pornputtapong7, Ruth Halaban8, Michael Krauthammer7,9, Rutao Cui4, D Timothy Bishop10, David J Adams1.
Abstract
The major genetic determinants of cutaneous melanoma risk in the general population are disruptive variants (R alleles) in the melanocortin 1 receptor (MC1R) gene. These alleles are also linked to red hair, freckling, and sun sensitivity, all of which are known melanoma phenotypic risk factors. Here we report that in melanomas and for somatic C>T mutations, a signature linked to sun exposure, the expected single-nucleotide variant count associated with the presence of an R allele is estimated to be 42% (95% CI, 15-76%) higher than that among persons without an R allele. This figure is comparable to the expected mutational burden associated with an additional 21 years of age. We also find significant and similar enrichment of non-C>T mutation classes supporting a role for additional mutagenic processes in melanoma development in individuals carrying R alleles.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27403562 PMCID: PMC4945874 DOI: 10.1038/ncomms12064
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919
Figure 1The distribution of SNV counts detected through exome sequencing of melanoma samples.
SNV counts are grouped by the presence of R alleles of the MC1R locus, and are shown as a boxplot with median, quartiles, whiskers and outliers. For each SNV class, the blue dashed line (and ribbon) charts the predicted mean mutation burden (and 95% confidence interval) of a patient with the most common constellation of values for clinical variables as the R allele count increases from zero to one or two, with all other clinical variables held fixed. (a) TCGA melanoma cohort, in which the most common constellation represents a 57-year-old male from the University of Sydney collection centre, with a metastasis to a regional lymph node of the extremities and a primary Breslow depth of 2.5 mm, Clark level IV, and no ulceration. Please note that one sample, TCGA-FW-A3R5, with R genotype 0/0 is an outlier with more than 10,000 C>T somatic mutations and is not depicted in the C>T panel of this image. (b) Yale Melanoma Project cohort, in which the most common constellation represents a 65 year-old male sampled via a metastasis.
Estimated multiplicative change in expected SNV count by R allele status adjusted for clinical and demographic variables.
Figure 2MC1R expression regulates the formation of mutagenic photoproducts.
(a) Shown are HPMs stably expressing control shRNA (shScr) or multiple independent shMC1Rs targeting MC1R (#1, #2, #3). Cells were pre-incubated with 1 μM α-MSH for 30 min, then exposed to 100 J m−2 UVB light, and harvested 3 h later for Western blot analysis. (b) HPM cells stably expressing shMC1R#1 were irradiated with different doses of UVB light as indicated. Cells were collected at 24 h after UVB light irradiation and viability assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (c) HPMs stably expressing an shRNA against MC1R (shMC1R#1) or a scrambled control (ShScr) were transfected with 2 μg of UV damaged pGL3 luciferase expression vector and 0.5 μg pRL Renilla Luciferase control reporter vector before the host cell reactivation assay2832 (Methods section; d,e). HPMs stably expressing an shRNA against MC1R (shMC1R#1) or a scrambled control (ShScr) were irradiated with 100 J m−2 UVB light and then collected at the different time points indicated. Genomic DNA was extracted and photoproducts were detected by ELISA. Cyclobutane pyrimidine dimer (CPD) (d) or 6–4 pyrimidine photoproduct (6–4PP) (e) antibodies were used (Methods section). These data were compiled from three separate experiments performed in triplicate. Significance (*P<0.05) was calculated by using the unpaired two-tailed Student's t-test comparing the means (shScr vs shMC1R#1) of the three experiments. Error bars represent s.d.